{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:20:36Z","timestamp":1707524436080},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,17]]},"DOI":"10.7759\/cureus.19666","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T16:48:24Z","timestamp":1637167704000},"source":"Crossref","is-referenced-by-count":0,"title":["Leptomeningeal Disease as an Initial Presenting Manifestation in Breast Cancer"],"prefix":"10.7759","author":[{"given":"Jasmine","family":"Shrestha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asis","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratul","family":"Karki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun E","year":"2017","unstructured":"Le Rhun E, Weller M, Brandsma D, et al.. EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017, 28:iv84-99. 10.1093\/annonc\/mdx221","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0408-4","article-title":"Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival","volume":"30","author":"Niwi\u0144ska A","year":"2013","unstructured":"Niwi\u0144ska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med Oncol. 2013, 30:408. 10.1007\/s12032-012-0408-4","journal-title":"Med Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4745","article-title":"Leptomeningeal carcinomatosis as the primary presentation of relapse in breast cancer","volume":"12","author":"Sacco K","year":"2016","unstructured":"Sacco K, Muhammad A, Saleem W, Alshaker H, Monzon L, Islam MR, Pchejetski D. Leptomeningeal carcinomatosis as the primary presentation of relapse in breast cancer. Oncol Lett. 2016, 12:779-82. 10.3892\/ol.2016.4745","journal-title":"Oncol Lett"},{"key":"ref4","article-title":"Leptomeningeal carcinomatosis can be presenting manifestation of breast carcinoma","volume":"73","author":"Stojmenovic GM","year":"2016","unstructured":"Stojmenovic GM, Pavlovic AM, Gazibara MS, Grujicic D, Radojicic A, Sternic NC. Leptomeningeal carcinomatosis can be presenting manifestation of breast carcinoma. Vojnosanit Pregl. 2016, 73:293-5.","journal-title":"Vojnosanit Pregl"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-207643","article-title":"Headache in a young woman: leptomeningeal metastasis as the first presentation of underlying breast malignancy","volume":"2015","author":"Mohan P","year":"2015","unstructured":"Mohan P, Antonelou M, Dadzie O, Dubrey S. Headache in a young woman: leptomeningeal metastasis as the first presentation of underlying breast malignancy. BMJ Case Rep. 2015, 2015:10.1136\/bcr-2014-207643","journal-title":"BMJ Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.01.020","article-title":"Leptomeningeal carcinomatosis in patients with breast cancer","volume":"135","author":"Franzoi MA","year":"2019","unstructured":"Franzoi MA, Hortobagyi GN. Leptomeningeal carcinomatosis in patients with breast cancer. Crit Rev Oncol Hematol. 2019, 135:85-94. 10.1016\/j.critrevonc.2019.01.020","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1179\/1973947812Y.0000000034","article-title":"Prognostic factors and clinical features in patients with leptominengeal metastases from breast cancer: a single center experience","volume":"24","author":"Meattini I","year":"2012","unstructured":"Meattini I, Livi L, Saieva C, et al.. Prognostic factors and clinical features in patients with leptominengeal metastases from breast cancer: a single center experience. J Chemother. 2012, 24:279-84. 10.1179\/1973947812Y.0000000034","journal-title":"J Chemother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq232","article-title":"Survival of breast cancer patients with meningeal carcinomatosis","volume":"21","author":"Gauthier H","year":"2010","unstructured":"Gauthier H, Guilhaume MN, Bidard FC, et al.. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol. 2010, 21:2183-7. 10.1093\/annonc\/mdq232","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3054-z","article-title":"Leptomeningeal disease and breast cancer: the importance of tumor subtype","volume":"146","author":"Abouharb S","year":"2014","unstructured":"Abouharb S, Ensor J, Loghin ME, et al.. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat. 2014, 146:477-86. 10.1007\/s10549-014-3054-z","journal-title":"Breast Cancer Res Treat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2016.07.002","article-title":"Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis","volume":"17","author":"Morikawa A","year":"2017","unstructured":"Morikawa A, Jordan L, Rozner R, Patil S, Boire A, Pentsova E, Seidman AD. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin Breast Cancer. 2017, 17:23-8. 10.1016\/j.clbc.2016.07.002","journal-title":"Clin Breast Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23088","article-title":"Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis","volume":"110","author":"Altundag K","year":"2007","unstructured":"Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007, 110:2640-7. 10.1002\/cncr.23088","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1175-6","article-title":"Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis","volume":"114","author":"Yust-Katz S","year":"2013","unstructured":"Yust-Katz S, Garciarena P, Liu D, et al.. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol. 2013, 114:229-35. 10.1007\/s11060-013-1175-6","journal-title":"J Neurooncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30420-6","article-title":"Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis","volume":"20","author":"Giuliano M","year":"2019","unstructured":"Giuliano M, Schettini F, Rognoni C, et al.. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019, 20:1360-9. 10.1016\/S1470-2045(19)30420-6","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge GW Jr","year":"2020","unstructured":"Sledge GW Jr, Toi M, Neven P, et al.. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020, 6:116-24. 10.1001\/jamaoncol.2019.4782","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors","volume":"6","author":"Patnaik A","year":"2016","unstructured":"Patnaik A, Rosen LS, Tolaney SM, et al.. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016, 6:740-53. 10.1158\/2159-8290.CD-16-0095","journal-title":"Cancer Discov"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.1019","article-title":"Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer","volume":"35","author":"Tolaney SM","year":"2017","unstructured":"Tolaney SM, Lin NU, Thornton D, Klise S, Costigan TM, Turner PK, Anders CK. Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer. J Clin Oncol. 2017, 35:1019. 10.1200\/JCO.2017.35.15_suppl.1019","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/76228-leptomeningeal-disease-as-an-initial-presenting-manifestation-in-breast-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:56Z","timestamp":1707506996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/76228-leptomeningeal-disease-as-an-initial-presenting-manifestation-in-breast-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.19666","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,17]]}}}